AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29450585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (1000 IU/day, orally)
Number of subjects: 160
Study 29450585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 25763988 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, clinic-integrated behavioural intervention
Number of subjects: 390
Study 25763988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 390
Study 25398189 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved chimney stoves
Number of subjects: 456
Study 25398189 — intervention group
Group type: COMPARATOR
Intervention: Traditional cookstoves
Number of subjects: 456
Study 23375025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept 320 mg SC plus indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days
Number of subjects: 225
Study 23375025 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9 days
Number of subjects: 225
Study 23375025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept 320 mg SC plus oral placebo
Number of subjects: 225
Study 21932656 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 228
Study 21932656 — intervention group
Group type: COMPARATOR
Intervention: Chisel osteotomy
Number of subjects: 228
Study 19363054 — intervention group
Group type: EXPERIMENTAL
Intervention: RVS pacing with VRR
Number of subjects: 24
Study 19363054 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing with VRR
Number of subjects: 24
Study 17004672 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental reading intervention daily for 50 minutes in small groups from October to April
Number of subjects: 0
Study 17004672 — intervention group
Group type: COMPARATOR
Intervention: School's existing instructional program for struggling readers
Number of subjects: 0
Study 15005325 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic induction (MI) low-cost system to measure liver iron overload; excitation magnetic field (B0, frequency: 28 kHz) produced by a coil.
Number of subjects: 17
Study 15005325 — intervention group
Group type: COMPARATOR
Intervention: Plastic tanks filled with water, saline, and ferric solutions for calibration purposes.
Number of subjects: 17
Study 11314793 — intervention group
Group type: EXPERIMENTAL
Intervention: rhOP‐1 (BMP‐7) with type I collagen carrier
Number of subjects: 122
Study 11314793 — intervention group
Group type: COMPARATOR
Intervention: Fresh autogenous bone
Number of subjects: 122
Study 11314793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 122
Study 9249116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS) 12.5 microg
Number of subjects: 18
Study 9249116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS) 25 microg
Number of subjects: 18
Study 9249116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS) 50 microg
Number of subjects: 18
Study 9249116 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ITS
Number of subjects: 18
Study 9249116 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen by nasal cannula
Number of subjects: 18
Study 9249116 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sufentanil concentrations
Number of subjects: 18
Study 8293750 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mgI/ml
Number of subjects: 80
Study 8293750 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 80
Study 3501994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100
Study 3501994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30696306 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin plus placebo
Number of subjects: 150
Study 30696306 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine plus placebo
Number of subjects: 150
Study 30696306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of indomethacin and nifedipine
Number of subjects: 150
Study 29420695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet daily
Number of subjects: 357
Study 29420695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet twice weekly with a postsex dose (time‐driven)
Number of subjects: 357
Study 29420695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet before and after sex (event‐driven)
Number of subjects: 357
Study 29420695 — intervention group
Group type: COMPARATOR
Intervention: Daily arm
Number of subjects: 357
Study 27733325 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Number of subjects: 60
Study 27733325 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP+perineural dexamethasone
Number of subjects: 60
Study 27733325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25555877 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined SGB group (group S, n=15)
Number of subjects: 30
Study 25555877 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia group (group N, n=15)
Number of subjects: 30
Study 23312702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 40
Study 23312702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20845241 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 3
Study 20845241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 20845241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 18837864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BFECT)
Number of subjects: 36
Study 18837864 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal ECT (BTECT)
Number of subjects: 36
Study 17003293 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin discontinued during exercise
Number of subjects: 49
Study 17003293 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin continued during exercise
Number of subjects: 49
Study 15535808 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful irrelevant speech
Number of subjects: 96
Study 15535808 — intervention group
Group type: EXPERIMENTAL
Intervention: Road traffic noise
Number of subjects: 96
Study 15535808 — intervention group
Group type: COMPARATOR
Intervention: Silent condition
Number of subjects: 96
Study 11754399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 22
Study 11754399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9282234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled ipratropium bromide (total dose of 144 micrograms)
Number of subjects: 18
Study 9282234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aminophylline (400 mg)
Number of subjects: 18
Study 9282234 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo and placebo tablets
Number of subjects: 18
Study 8102213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol 4 mg after placebo
Number of subjects: 14
Study 8102213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 4 mg after placebo
Number of subjects: 14
Study 8102213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol 4 mg after atenolol
Number of subjects: 14
Study 8102213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 4 mg after atenolol
Number of subjects: 14
Study 8102213 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fenoterol and salbutamol at both doses
Number of subjects: 14
Study 3557779 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for 14 h/week
Number of subjects: 38
Study 3557779 — intervention group
Group type: COMPARATOR
Intervention: Training for 7 h/week
Number of subjects: 38
Study 31696260 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E blended highly cross-linked ultra-high molecular weight polyethylene liners (UHMWPE‐XE)
Number of subjects: 143
Study 31696260 — intervention group
Group type: COMPARATOR
Intervention: Conventional highly cross-linked polyethylene liners (UHMWPE‑X)
Number of subjects: 143
Study 30670102 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention plus TIPs for 12 weeks
Number of subjects: 1076
Study 30670102 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention plus text-message-initiated assessment of alcohol consumption for 12 weeks
Number of subjects: 1076
Study 30670102 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention only
Number of subjects: 1076
Study 30670102 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-related psychoeducation
Number of subjects: 1076
Study 29658242 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz TEAS
Number of subjects: 72
Study 29658242 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS
Number of subjects: 72
Study 25774807 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory treatment (experimental group)
Number of subjects: 307
Study 25774807 — intervention group
Group type: COMPARATOR
Intervention: Educational hand hygiene leaflets (control group)
Number of subjects: 307
Study 23321647 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐blockade and losartan (BB-L)
Number of subjects: 28
Study 23321647 — intervention group
Group type: COMPARATOR
Intervention: β‐blockade (BB)
Number of subjects: 28
Study 20795875 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT present video information
Number of subjects: 71
Study 20795875 — intervention group
Group type: COMPARATOR
Intervention: Non-PMT information about ankle sprains
Number of subjects: 71
Study 20795875 — intervention group
Group type: COMPARATOR
Intervention: No formal information
Number of subjects: 71
Study 19820133 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein (CRP) in the fourth quartile
Number of subjects: 3795
Study 19820133 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function
Number of subjects: 3795
Study 16741212 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 28
Study 16741212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15063959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution misoprostol 400 microg
Number of subjects: 50
Study 15063959 — intervention group
Group type: COMPARATOR
Intervention: Oral tablet misoprostol 400 microg
Number of subjects: 50
Study 15063959 — intervention group
Group type: COMPARATOR
Intervention: Rectal misoprostol 400 microg
Number of subjects: 50
Study 15063959 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg
Number of subjects: 50
Study 15063959 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular syntometrine 1 ml
Number of subjects: 50
Study 11213881 — intervention group
Group type: EXPERIMENTAL
Intervention: Graftskin
Number of subjects: 208
Study 11213881 — intervention group
Group type: COMPARATOR
Intervention: Control (saline-moistened gauze)
Number of subjects: 208
Study 9562133 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin mixed with fat-free chocolate pudding (phase IV)
Number of subjects: 9
Study 9562133 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (control, phase I)
Number of subjects: 9
Study 9562133 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin mixed with protein (phase IV)
Number of subjects: 9
Study 7515453 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of 100 to 250 micrograms/day of G‐CSF, 400 to 800 mg/day of MCZ, and various antibiotics (Group I)
Number of subjects: 15
Study 7515453 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of 400 to 800 mg/day of MCZ, 100 to 250 micrograms/day of G‐CSF, and various antibiotics (Group II)
Number of subjects: 15
Study 7515453 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of 200 to 1,200 mg/day of MCZ and various antibiotics (Group III)
Number of subjects: 15
Study 7515453 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of 400 to 800 mg/day of MCZ and various antibiotics (Group III)
Number of subjects: 15
Study 7515453 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF administration in 7 patients
Number of subjects: 15
Study 7515453 — intervention group
Group type: EXPERIMENTAL
Intervention: MCZ and antibiotics
Number of subjects: 15
Study 7515453 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic modality
Number of subjects: 15
Study 3334047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bone alignment device (group A)
Number of subjects: 116
Study 3334047 — intervention group
Group type: COMPARATOR
Intervention: Manual reduction with local infiltration anaesthesia (group B)
Number of subjects: 116
Study 29131316 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV screening and vaccination multicomponent intervention
Number of subjects: 1834
Study 29131316 — intervention group
Group type: COMPARATOR
Intervention: General cancer education control
Number of subjects: 1834
Study 27168267 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell-derived skin lineage precursor secretions incorporated in serum and lotion
Number of subjects: 50
Study 27168267 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard treatment not specified)
Number of subjects: 50
Study 25024196 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies leading to asymmetric payoffs played by participants from India
Number of subjects: 1000
Study 25024196 — intervention group
Group type: COMPARATOR
Intervention: Strategies leading to symmetric payoffs played by participants from the United States
Number of subjects: 1000
Study 25024196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted to play asymmetrically by participants from India
Number of subjects: 1000
Study 25024196 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching with other study participants from their own population
Number of subjects: 1000
Study 22670050 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009-2010 seasonal trivalent inactivated influenza vaccine (TIV)
Number of subjects: 796
Study 20576697 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy group
Number of subjects: 683
Study 20576697 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple system atrophy group
Number of subjects: 683
Study 20576697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 683
Study 18702556 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parent Training Program with developmental delay modifications (12-week duration)
Number of subjects: 44
Study 18702556 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including early childhood education and related services)
Number of subjects: 44
Study 15702297 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosimetry system (CONV)
Number of subjects: 17
Study 15702297 — intervention group
Group type: EXPERIMENTAL
Intervention: Paris dosimetry system (PDS)
Number of subjects: 17
Study 15702297 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometrically optimized system (GOS)
Number of subjects: 17
Study 15702297 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal system (CONF)
Number of subjects: 17
Study 12734690 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) injection 10 min before the second dose of N-isopropyl-[123I] p-iodoamphetamine (IMP)
Number of subjects: 33
Study 12734690 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard input function (F(SIF)) calibrated with continuously drawn arterial blood sample
Number of subjects: 33
Study 12734690 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard input function (F(SIF)) calibrated with a single arterial blood sample
Number of subjects: 33
Study 12734690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-table ARG method
Number of subjects: 33
Study 10227003 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hormone replacement therapy (HRT)
Number of subjects: 62
Study 10227003 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cream of estriol
Number of subjects: 62
Study 10227003 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study 8564973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. daily or every other day
Number of subjects: 49
Study 8564973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. at 175 mg/m2/day (liquid formulation)
Number of subjects: 49
Study 8564973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. at 125 mg/m2/day (gelatin capsule formulation)
Number of subjects: 49
Study 8564973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. at 330 mg/m2 every‐other‐day (liquid formulation)
Number of subjects: 49
Study 8564973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI)
Number of subjects: 49
Study 1715153 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal VDRL titre of 1:32 or above
Number of subjects: 0
Study 1715153 — intervention group
Group type: COMPARATOR
Intervention: Untreated mothers
Number of subjects: 0
Study 1715153 — intervention group
Group type: COMPARATOR
Intervention: Low birthweight
Number of subjects: 0
Study 6137227 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg kg‐1
Number of subjects: 0
Study 6137227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg kg‐1
Number of subjects: 0
Study 6137227 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Midazolam and Diazepam
Number of subjects: 0
Study 30721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic improvement defined by absence of erosion or ulceration, absence of crypt destruction, and <5% of crypts with epithelial neutrophil infiltration in the PURSUIT‐SC trial.
Number of subjects: 420
Study 30721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic improvement at Week 8 in JAK‐UC trial.
Number of subjects: 420
Study 30721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic improvement at Week 4 in JAK‐UC trial.
Number of subjects: 420
Study 30721964 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic improvement at Week 6 in PROgECT trial.
Number of subjects: 420
Study 30521632 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages focused on personal agency
Number of subjects: 12316
Study 30521632 — intervention group
Group type: COMPARATOR
Intervention: Messages focused on communion
Number of subjects: 12316
Study 26607941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar diet (replacing 40% of calories from simple sugars with fats, proteins, and complex carbohydrates)
Number of subjects: 33
Study 26607941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar diet
Number of subjects: 33
Study 26607941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in sugar intake)
Number of subjects: 33
Study 26607941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar diet and Control group
Number of subjects: 33
Study 24610180 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit association test before decision
Number of subjects: 543
Study 24610180 — intervention group
Group type: COMPARATOR
Intervention: Black patient
Number of subjects: 543
Study 24610180 — intervention group
Group type: COMPARATOR
Intervention: White patient
Number of subjects: 543
Study 24610180 — intervention group
Group type: COMPARATOR
Intervention: Implicit racial bias
Number of subjects: 543
Study 24610180 — intervention group
Group type: COMPARATOR
Intervention: Explicit racial bias
Number of subjects: 543
Study 24610180 — intervention group
Group type: COMPARATOR
Intervention: Medical cooperativeness stereotypes
Number of subjects: 543
Study 22584263 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl glucoside (GG) 5% applied topically
Number of subjects: 0
Study 22584263 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl glucoside (GG) 3% w/v in cultured human keratinocytes
Number of subjects: 0
Study 20470272 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17638394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50mg twice daily
Number of subjects: 370
Study 17638394 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75mg twice daily
Number of subjects: 370
Study 15618066 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary angiography
Number of subjects: 1609
Study 15618066 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive treatment (no early coronary angiography)
Number of subjects: 1609
Study 12901810 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective plastic oral guard
Number of subjects: 34
Study 12901810 — intervention group
Group type: COMPARATOR
Intervention: No guard (Control)
Number of subjects: 34
Study 10326953 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 1637
Study 10326953 — intervention group
Group type: COMPARATOR
Intervention: Close observation
Number of subjects: 1637
Study 8547445 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 8
Study 8547445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8547445 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone
Number of subjects: 8
Study 1662959 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole once a day
Number of subjects: 111
Study 1662959 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ketoconazole twice a day
Number of subjects: 111
Study 6161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 8
Study 6161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylene 1200 mg/m3 + Alcohol 0.8 g/kg
Number of subjects: 8
Study 6161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylene 700 mg/m3 + Alcohol 0.8 g/kg
Number of subjects: 8
Study 6161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylene 1200 mg/m3 alone
Number of subjects: 8
Study 6161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol alone (0.4 g/kg and 0.8 g/kg)
Number of subjects: 8